SETTING: A tuberculosis (TB) referral hospital in South Korea. OBJECTIVE: To evaluate predictors of treatment outcomes and survival among non-human immunodeficiency virus (HIV) infected patients with extensively drug-resistant TB (XDR-TB). DESIGN: Patients who were diagnosed with XDR-TB at the National Masan Tuberculosis Hospital from January 2001 to December 2005 were included in this study. We conducted a retrospective review of their medical records and mortality data. RESULTS: A total of 176 non-HIV-infected patients with XDR-TB were included. TB-related mortality was 48% (84/176), and the median survival time from the diagnosis date of XDR-TB was 51 months (range 0-127, 95%CI 32.53-69.47). Cure and treatment completion were classified as favourable outcome and treatment failure, death during treatment and default as poor outcome. Previous TB treatment with second-line drugs (aOR 2.76, 95%CI 1.02-7.44) and cavitary disease (aOR 3.01, 95%CI 1.12-8.08) were independent risk factors for poor outcome. Use of linezolid (aOR 0.10, 95%CI 0.01-0.69) and surgical resection (aOR 0.18, 95%CI 0.04-0.78) were associated with favourable outcome. CONCLUSION: There was high mortality in non-HIV-infected patients with XDR-TB at a TB referral hospital in South Korea. Adjunctive surgical treatment and linezolid improved the outcome for selected patients with XDR-TB.
SETTING: A tuberculosis (TB) referral hospital in South Korea. OBJECTIVE: To evaluate predictors of treatment outcomes and survival among non-human immunodeficiency virus (HIV) infectedpatients with extensively drug-resistant TB (XDR-TB). DESIGN:Patients who were diagnosed with XDR-TB at the National Masan Tuberculosis Hospital from January 2001 to December 2005 were included in this study. We conducted a retrospective review of their medical records and mortality data. RESULTS: A total of 176 non-HIV-infectedpatients with XDR-TB were included. TB-related mortality was 48% (84/176), and the median survival time from the diagnosis date of XDR-TB was 51 months (range 0-127, 95%CI 32.53-69.47). Cure and treatment completion were classified as favourable outcome and treatment failure, death during treatment and default as poor outcome. Previous TB treatment with second-line drugs (aOR 2.76, 95%CI 1.02-7.44) and cavitary disease (aOR 3.01, 95%CI 1.12-8.08) were independent risk factors for poor outcome. Use of linezolid (aOR 0.10, 95%CI 0.01-0.69) and surgical resection (aOR 0.18, 95%CI 0.04-0.78) were associated with favourable outcome. CONCLUSION: There was high mortality in non-HIV-infectedpatients with XDR-TB at a TB referral hospital in South Korea. Adjunctive surgical treatment and linezolid improved the outcome for selected patients with XDR-TB.
Authors: Karen R Jacobson; Dylan B Tierney; Christie Y Jeon; Carole D Mitnick; Megan B Murray Journal: Clin Infect Dis Date: 2010-07-01 Impact factor: 9.079
Authors: Medea Gegia; Iagor Kalandadze; Russel R Kempker; Matthew J Magee; Henry M Blumberg Journal: Int J Infect Dis Date: 2012-03-17 Impact factor: 3.623
Authors: Sharon Y Wong; Jong Seok Lee; Hyun Kyung Kwak; Laura E Via; Helena I M Boshoff; Clifton E Barry Journal: Antimicrob Agents Chemother Date: 2011-03-28 Impact factor: 5.191
Authors: M W Carroll; M Lee; Y Cai; C W Hallahan; P A Shaw; J H Min; L C Goldfeder; V Alekseyev; S Grinkrug; H S Kang; S Hwang; H-M Park; E Kang; S-Y Lee; B Jin; H-E Park; S Min; S K Park; D S Jeon; L E Via; C E Barry Journal: Int J Tuberc Lung Dis Date: 2012-05-08 Impact factor: 2.373
Authors: Laura E Via; Sang-Nae Cho; Soohee Hwang; Hyeeun Bang; Seung Kyu Park; Hyung Seok Kang; Doosoo Jeon; Seon Yeong Min; Taegwon Oh; Yeun Kim; Young Mi Kim; Vignesh Rajan; Sharon Y Wong; Isdore Chola Shamputa; Matthew Carroll; Lisa Goldfeder; Song A Lee; Steven M Holland; Seokyong Eum; Hyeyoung Lee; Clifton E Barry Journal: J Clin Microbiol Date: 2009-12-23 Impact factor: 5.948
Authors: Sheela V Shenoi; Ralph P Brooks; Russell Barbour; Frederick L Altice; Daniel Zelterman; Anthony P Moll; Iqbal Master; Theo L van der Merwe; Gerald H Friedland Journal: PLoS One Date: 2012-03-06 Impact factor: 3.240
Authors: Max R O'Donnell; Nesri Padayatchi; Charlotte Kvasnovsky; Lise Werner; Iqbal Master; C Robert Horsburgh Journal: Emerg Infect Dis Date: 2013-03 Impact factor: 6.883